• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Exposure to particulate matter 2.5 μm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

byZoya GomesandYuchen Dai
October 27, 2022
in Chronic Disease, Public Health, Pulmonology
Reading Time: 3 mins read
Lessons from real-world implementation of lung cancer screening
Share on FacebookShare on Twitter

1. Increasing exposure to sulfate, nitrate, and ammonium particulate matter 2.5 μm (PM2.5 μm) constituents was associated with adverse outcomes among patients with fibrotic interstitial lung disease with respect to baseline severity, disease progression, and had increased mortality across all 3 cohorts.

2. A PM2.5 μm exposure of 8μg/m3 or more was associated with a hazard ratio for mortality of 4.40 in the Simmons cohort, 1.71 in the Pulmonary Fibrosis Foundation cohort, and 1.45 in the Canadian Registry for Pulmonary Fibrosis Foundation cohort.

Evidence Rating Level: 2 (Good)

Study Rundown: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of fibrotic interstitial lung disease (fILD), a group of pulmonary conditions characterized by dyspnea, radiographic pulmonary fibrosis and high mortality. Air pollution is known to be associated with IPF development and progression, and particulate matter 2.5 μm (PM2.5) is estimated to be responsible for up to 8.9 million premature deaths annually. This multicenter prospective cohort study investigated the association of PM2.5 exposure with mortality and lung function among patients with fILD. A total of 6683 patients with fILD were included from various registries, and data was analyzed from June 1, 2021, to August 2, 2022. The primary exposure was PM2.5 and its constituents. The main measures were multivariable linear regression to test exposures 5 years before enrollment with baseline forced vital capacity (FVC) and diffusion capacity for carbon monoxide. A PM2.5 μm exposure of 8μg/m3 or more was associated with a hazard ratio for mortality of 4.40 in the Simmons cohort, 1.71 in the Pulmonary Fibrosis Foundation cohort (PFF), and 1.45 in the Canadian Registry for Pulmonary Fibrosis Foundation cohort (CARE-PF). It was found that increasing exposure to sulfate, nitrate, and ammonium PM2.5 μm constituents was associated with increased mortality across all cohorts. Meta-analyses further revealed that exposure to sulfate and ammonium was associated with the rate of decrease in FVC, diffusion capacity of carbon monoxide, and an association of increasing levels of PM2.5 μm. A strength of this study was that it represents the largest and most geographically diverse evaluation of the associations between PM2.5 μm and disease in patients with diverse forms of fILD. A limitation of this study was that pollution exposures were estimated at a patient’s most recent residential address but neglects to account for changes in address, leading to the potential risk of exposure misclassification.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Air pollution and interstitial lung diseases: defining epigenomic effects

RELATED REPORTS

Chronic exposure to particulate matter is associated with increased cardiovascular risk

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

In-Depth [prospective cohort]: This study investigated the association of PM2.5 μm exposure with mortality and lung function in patients with fILD. There was a total of 6683 patients in the cohort (3653 [55%] men, the median age at enrollment was 66 (58-73 years). The 3 cohorts included Simmons (n=1424), Pulmonary Fibrosis Foundation (n=1870), and the Canadian Registry for Pulmonary Fibrosis (n=3389).  The median follow-up across the 3 cohorts was 2.9 years (IQR, 1.5-4.5 years), which included 28% of patient death and 10% of patients had lung transplants. The main measures included a multivariable linear regression to test associations of exposures 5 years before enrollment with baseline forced vital capacity and diffusion capacity for carbon monoxide. Additionally, multivariable Cox models were used to test associations of exposure with a decrease in lung function. A PM2.5 μm exposure of 8μg/m3 or more was associated with increased mortality, Simmons cohort (HR, 4.40 [95% CI, 3.51-5.51]; P <.001; PFF cohort HR, 1.71 [95% CI, 1.32-2.21] P < .001; CARE-PF cohort HR, 1.45 [95% CI, 1.18-1.79]; P <.001). In adjusted Simmons cohort models, it was found that an increase of 1μg/m3 in the 5-year pre-enrollment PM2.5 μm level was associated with a 0.98% lower estimated percentage baseline FVC (95% CI, -1.45 to 0.50; P <.001), but was not shown to be significant in the PFF or CARE-PF cohorts. Upon evaluating the association of PM2.5 μm and its constituents with a decrease in lung function, each increase of 1μg/m3 in 5-year precensoring PM2.5 μm exposure in the Simmons cohort was associated with an additional 0.4% decrease in FVC percentage per year (95% CI, -0.53 to -0.27; P <.001), however, it was not observed in the PFF or CARE-PF cohorts.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: fibrosing interstitial lung diseaseidiopathic pulmonary fibrosismortalityparticulate matter
Previous Post

#VisualAbstract: Higher mean arterial blood pressure targets did not improve outcomes in comatose survivors of cardiac arrest

Next Post

Comparable initial effectiveness between initial CT and coronary angiography for major adverse cardiovascular events

RelatedReports

Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
“Housing First” linked to housing stability for homeless youth with mental illness
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Hematologic inflammatory indices may predict prognosis in younger patients with COVID-19 but not older patients

August 4, 2026
Next Post
Colchicine may lower the risk of cardiovascular events in patients with coronary disease

Comparable initial effectiveness between initial CT and coronary angiography for major adverse cardiovascular events

The experience of spirituality may positively impact the lives of terminal cancer patients

#VisualAbstract: Continuous glucose monitoring in type 1 diabetes results in improved blood glucose levels

#VisualAbstract: Continuous glucose monitoring in type 1 diabetes results in improved blood glucose levels

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic exposure to particulate matter is associated with increased cardiovascular risk
  • Deep-learning model achieved high diagnostic performance for diabetic macular edema detection using optical coherence tomography (OCT) scans
  • FDA-cleared AI devices rarely have patient outcome data
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.